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Abstract It is important to adequately and timely identify
individuals with cancer worries amongst participants in a
pancreatic ductal adenocarcinoma (PDAC) surveillance
program, because they could benefit from psychosocial
support to decrease distress. Therefore, the aim of this
study was to assess both psychosocial and clinical factors
associated with cancer worries. High-risk individuals par-
ticipating in PDAC-surveillance were invited to annually
complete a cancer worry scale (CWS) questionnaire which
was sent after counseling by the clinical geneticist (T0),
after intake for participation in PDAC-surveillance (T1),
and then annually after every MRI and endoscopic ultra-
sonography (EUS) (T2 and further). Analyses were per-
formed to identify factors associated with cancer worries in
the second year of surveillance (T3). We found a signifi-
cant intra-individual decrease in cancer worries
(b = -0.84, P\ 0.001), nevertheless, 33 % of individuals
had a CWS-score C14 at T3. We found one factor signif-
icantly associated with cancer worries at T3: having a
family member affected by PDAC \50 years of age
(b = 0.22, P = 0.03). The detection of a cystic lesion, a
shortened surveillance interval, or undergoing pancreatic
surgery did not lead to more cancer worries (P = 0.163,
P = 0.33, and P = 0.53, respectively). In conclusion, this
study identified ‘a family history of PDAC\50 years of
age’ as the only predictor of cancer worries experienced
after 2 years of surveillance in individuals at high risk of
developing PDAC. This knowledge could help clinicians to
timely identify individuals ‘at risk’ for high levels of
cancer worries who would likely benefit from psychosocial
support.
Keywords Cancer worries  Pancreatic cancer 
Surveillance  High-risk individuals  Psychosocial burden 
Predictive factors
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a deadly
disease: despite its relatively low incidence of 10–12 new
cases per 100,000 persons/year [1–3], PDAC is ranked
among the top five causes of cancer-related deaths [4, 5].
Its 5-year survival rate has not significantly improved over
the past decades and is less than 6 % [4, 5]. Since survival
rates strongly depend on the stage of PDAC when detected,
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there is globally an increasing interest in surveillance to
detect PDAC or its precursor high-grade dysplastic lesions
at an early stage. Although screening of the entire popu-
lation for PDAC is unlikely to be feasible because of the
lack of a non-invasive, reliable and affordable surveillance
tool, surveillance of well-defined high-risk groups for
PDAC might be effective.
Two specific groups of individuals are considered to be
at high risk of developing PDAC: (1) mutation carriers of
hereditary syndromes that increase the risk of developing
PDAC (i.e. carriers of mutations in the CDKN2A, BRCA1,
BRCA2 or TP53 gene, and individuals with Peutz–Jeghers
or Lynch syndrome), and (2) individuals without a known
gene mutation but who have a strong family history of
PDAC [familial pancreatic cancer (FPC)]. In these indi-
viduals, the risk of developing PDAC can be up to 75-fold
higher than in the general population [6–13].
Over the past decades, multiple studies into the effec-
tiveness of surveillance for PDAC in high-risk individuals
have been performed [14–25]. Importantly, however, when
assessing the effectiveness of a surveillance program, one
should also take into account the psychological aspects of
repeated participation in such a surveillance program. We
previously reported that repeated participation in annual
surveillance imposed low psychological burden on indi-
viduals at high risk for PDAC. However, we did find that a
third of the participants had moderate to high cancer
worries [26].
As individuals with high levels of cancer worries might
benefit from psychosocial support to decrease the levels of
psychological distress, it could be essential to adequately
and timely identify these individuals. Therefore, the aim of
this study was (1) to evaluate the course of cancer worries
over a 2-year period of PDAC-surveillance (2) to identify
psychosocial factors associated with cancer worries, and
(3) to assess the impact of pancreatic cystic lesion detec-
tion, a recommended shortened surveillance interval, and
undergoing pancreatic surgery on cancer worries in high-
risk individuals participating in annual PDAC-surveillance.
Methods
Participants
All participants of an ongoing Dutch pancreatic cancer
surveillance study (FPC-study) were invited to participate
in a psychological questionnaire study as previously
described [26]. The FPC-study is an ongoing multicenter
prospective study investigating the effectiveness of PDAC-
surveillance in high-risk individuals. Eligible for inclusion
in this study are asymptomatic individuals with an esti-
mated familial or hereditary life-time risk of developing
PDAC C10 % (see inclusion criteria in Table 1). The
minimal age for inclusion between 2008 and 2013 was
45 years of age (or 30 years in case of Peutz–Jeghers
syndrome) or 10 years younger than the age of the
youngest relative with PDAC, whichever age occurred first.
Since 2013, the minimal age for inclusion is 50 or 10 years
younger than the age of the youngest relative with PDAC.
Surveillance ends at the age of 75. All potential candidates
are evaluated by a clinical geneticist prior to inclusion.
They are informed that the effectiveness of PDAC
surveillance in reducing morbidity and mortality is not yet
proven.
Clinical study procedures
The clinical study procedures were previously extensively
described [25]. In summary, annual surveillance of the
pancreas is performed using endoscopic ultrasonography
(EUS), carried out by experienced endosonographers, and
magnetic resonance imaging (MRI) with intravenous
administration of gadobutrol. EUS is performed under
conscious (midazolam/fentanyl) or propofol sedation.
Some participants undergo surveillance with only MRI or
EUS (see Table 2) due to contra-indications for either
modality (for example claustrophobia, pacemaker or dis-
comfort during initial EUS). Follow-up policy is based on
the agreement of an expert panel consisting of endosono-
graphists, surgeons, radiologists and pathologists and is as
follows:
1. Annual surveillance when either no pancreatic abnor-
malities or cystic lesions\10 mm are detected;
2. Interval surveillance after 6 months when a novel
cystic lesion is detected with a diameter of 10–30 mm
without worrisome features;
3. Interval surveillance after 3 months when a lesion of
unknown significance is detected for which there is no
unanimous opinion amongst members of the expert
panel;
4. Surgical resection in case of 1. a solid lesion which is
considered suspicious for malignancy, 2. a cystic
lesion C30 mm, 3. a cystic lesion with worrisome
features (thickened/enhanced cyst wall and/or mural
nodules), or 4. a main branch intraductal papillary
mucinous neoplasm (IPMN, main pancreatic duct
C10 mm).
Questionnaire study
All participants of the ongoing PDAC-surveillance study
are invited to participate in the ongoing prospective mul-
ticenter psychological questionnaire study. Participants
receive a first questionnaire on sociodemographic data after
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their counseling session with the clinical geneticist (T0), a
second questionnaire after explanation of the study proce-
dures by the gastroenterologist (T1), and then annually
after receiving their surveillance results (T2 and further),
see also Fig. 1. Because this questionnaire study was added
after the first inclusion period of the original clinical study
protocol, some participants had already had their first
investigations and therefore started their questionnaires at
T2.
All measurements used in the questionnaires were pre-
viously described [26]. We report here the results of the
cancer-related worries as assessed with the eight-item
cancer worry scale (CWS) [27, 28]. The items of the CWS
are shown in Table 3. The total CWS-score ranges from 8
to 32, with higher scores indicating more frequent worries
about cancer. There is no clear cut-off point for the CWS-
score, nevertheless, a score C14 could be indicative of
moderate to high levels of cancer worries [29]. The
Cronbach’s alpha, a measure of internal consistency with
values[0.70 being considered acceptable, was high for the
CWS in the current sample at T3 (0.86, n = 121).
The ethical committee of all participating centers
approved the study protocol and the study was conducted
in accordance with the declaration of Helsinki. All partic-
ipants gave written informed consent prior to the perfor-
mance of any study-related investigations.
Statistical analyses
Questionnaires were analyzed using descriptive statistics.
Intra-individual change in cancer worries over time was
assessed with a mixed-effect model (growth curve model)
with a maximum likelihood estimator and unstructured
covariance matrix. Univariate and multivariate regression
analyses were performed to identify sociodemographic
factors from the questionnaires T0, T1 and/or T2 that were
associated with cancer worries at the second year of fol-
low-up (T3). For these analyses, we selected all partici-
pants who returned the T3 questionnaire as well as at least
a T0, T1 or T2 questionnaire. To analyze the impact on
cancer worries of the detection of a pancreatic cystic
lesion, a recommended shortened surveillance interval, and
undergoing pancreatic surgery, we selected all participants
who returned the questionnaire in the year of the event (i.e.
the detection of a cyst and/or an advised shortened
surveillance interval and/or undergoing pancreatic surgery;
the questionnaire was sent after participants had received
their surveillance results) and who returned the question-
naire 1 year before and/or 1 year after the event. A paired-
samples T test was performed for these analyses. In all
analyses, a P value \0.05 was considered statistically
significant. All analyses were conducted using the statis-
tical package for the social sciences (version 21, SPSS
Institute, Chicago, IL).
Results
Participants’ characteristics
In March 2015, 166 individuals participated in the ques-
tionnaire study. Baseline characteristics of all individuals
are summarized in Table 2. Mean age of all 166 partici-
pants at inclusion in the clinical study was 51 years, of
whom 47 (28 %) were treated for cancer (predominantly
for melanoma or breast cancer) prior to inclusion in the
study.
Cancer worries
The scores per item on the CWS-questionnaires are shown
in Table 3. The mean CWS-score was 14 at T0, 14 at T1,
13 at T2, and 12 at T3; the overall average CWS-score was
13. We found a significant intra-individual decrease in the
CWS-score over time (b = -0.84, P\ 0.001). Thirty-nine
individuals (33 %) had a CWS-score C14 in the second
year of follow-up (T3), this was 51, 52 and 43 % at T0, T1
and T2, respectively.
Table 1 Inclusion criteria for the pancreatic cancer surveillance study
Carriers of CDKN2A gene mutations, regardless of the family history of PDAC
Peutz–Jeghers syndrome patients (diagnosis based on a proven LKB1/STK11 gene mutation or clinical signs), regardless of the family history
of PDAC
Carriers of gene mutations in BRCA1, BRCA2, TP53, or Mismatch Repair genes with a family history of PDAC in C2 family members
Individuals with C2 relatives affected by pancreatic cancer who were related in the first degree to each other, of which at least one was related
in the first-degree to the eligible individual
Individuals with C3 relatives affected by pancreatic cancer who were related in the first or second degree to each other, of which at least one
was related in the first-degree to the eligible individual
Individuals with C2 relatives affected by pancreatic cancer who were related in the second degree to each other, of which at least one was
related in the first-degree to the eligible individual and at least one was aged under 50 years at time of diagnosis
PDAC pancreatic ductal adenocarcinoma
Factors associated with cancer worries in individuals participating in annual pancreatic… 145
123
Table 2 Baseline characteristics of study participants
All individuals
(n = 166) N (%)
Individuals with the T0,
T1 and/or T2 AND the T3
questionnaire (n = 117) N (%)
Individuals without the T0,
T1 and/or T2 NOR the T3
questionnaire (n = 49) N (%)
P value
(n = 117
vs. n = 49)
Age at inclusion, mean (range, SD) 51 (19–73, 9.7) 51 (19–73, 9.5) 51 (30–72, 10.3) 0.894
Gender, male 68 (41 %) 50 (43 %) 18 (37 %) 0.473
Genetic background
Familial pancreatic cancer (FPC) 84 (51 %) 60 (51 %) 24 (49 %)
CDKN2A (FAMMM syndrome) 44 (27 %) 32 (27 %) 12 (25 %)
BRCA1 (HBOC) 2 (1 %) 2 (2 %) 0 (0 %)
BRCA2 (HBOC) 25 (15 %) 17 (15 %) 8 (16 %)
LKB1 (Peutz–Jeghers syndrome) 7 (4 %) 4 (3 %) 3 (6 %)
TP53 (Li Fraumeni syndrome) 4 (2 %) 2 (2 %) 2 (4 %) 0.783
Number of PDAC cases in the
family, mean (range, SD)
2 (0–7, 1.2) 2 (0–7, 1.2) 2 (0–5, 1.2) 0.202
Youngest family member affected
by PDAC, mean (range, SD)
51 (21–89, 11.4) 51 (21–89, 11.4) 53 (40–80, 11.4) 0.357
Children
Yes 136 (82 %) 104 (89 %) 32 (65 %)
No 20 (12 %) 11 (9 %) 9 (18 %)
No data 10 (6 %) 2 (2 %) 8 (16 %) 0.042
Marital status
Married/co-habiting/LAT
relationship
129 (78 %) 98 (84 %) 31 (63 %)
Single/divorced/widowed 19 (11 %) 11 (9 %) 8 (16 %)
No data 18 (11 %) 8 (7 %) 10 (20 %) 0.095
Level of education
Primary school 3 (2 %) 3 (3 %) 0 (0 %)
High school 39 (24 %) 27 (23 %) 12 (25 %)
College/university 115 (69 %) 85 (73 %) 30 (61 %)
No data 9 (5 %) 2 (2 %) 7 (14 %) 0.486
Smoking behavior
Never smoker 85 (51 %) 60 (51 %) 25 (51 %)
Current or past smoker 67 (40 %) 50 (43 %) 17 (35 %)
No data 14 (8 %) 7 (6 %) 7 (14 %) 0.580
Alcohol consuming
Never consumer 37 (22 %) 30 (26 %) 7 (14 %)
Current or past consumer 114 (69 %) 81 (69 %) 33 (67 %)
No data 15 (9 %) 6 (5 %) 9 (18 %) 0.230
Ever treated for cancer
Any type of cancer 47 (28 %) 35 (30 %) 12 (25 %)
Melanoma 28 (17 %) 20 (17 %) 8 (16 %)
Breast cancer 13 (8 %) 10 (9 %) 3 (6 %)
Other 10 (6 %) 9 (8 %) 1 (2 %) 0.479
Surveillance with
EUS & MRI 159 (96 %) 112 (96 %) 47 (96 %)
EUS only 2 (1 %) 2 (2 %) 0 (0 %)
MRI only 5 (3 %) 3 (3 %) 2 (4 %) 0.576
SD standard deviation, FAMMM familial atypical multiple mole melanoma, HBOC hereditary breast and ovarian cancer, PDAC pancreatic ductal
adenocarcinoma, LAT living apart together, EUS endoscopic ultrasonography, MRI magnetic resonance imaging
Bold P-values are considered statistically significant
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Factors associated with cancer worries at the second
year of follow-up
For these sub-analyses, we only included individuals with a
T3 assessment, as well as at least a T0, T1 or T2 assessment.
Of the 166 individuals that participated in the questionnaire
study, 117 individuals returned the T3 questionnaire as well
as at least a T0, T1 and/or T2 questionnaire (response 70 %).
Baseline characteristics for these 117 individuals selected for
sub-analyses, and for the 49 individuals without the required
questionnaires, are summarized in Table 2. The subgroup of
117 individuals only differed in comparison to the excluded
individuals (n = 49) on having children (89 % of the
included individuals had children vs. 65 % of excluded
individuals, P = 0.04).
For the selection of possible predictors of cancer worries
in the second year of follow-up (T3), we performed uni-
variate regression analyses. Significant predictors were
‘having a familymember affected by PDACbelow the age of
500 (b = 0.23, P = 0.01), and ‘a perceived elevated risk of
developing PDAC’ (b = 0.23, P = 0.01). Not predictive
were, amongst other factors, the number of PDAC-cases in
the family and a personal history of cancer, see also Table 4.
In the next step, the two significant predictors were included
in the multivariate model, together with age, gender and
genetic background. In this multivariate analysis (see
Table 4), having a family member affected by PDAC below
the age of 50 was associated with cancer worries in the
second year of follow-up (b = 0.22, P = 0.03). Figure 2
shows the mean CWS-score per questionnaire for all indi-
viduals and for individuals with and without a family
member affected by PDAC\50 years of age.
Impact of the detection of a pancreatic cystic lesion
on cancer worries
In 93 out of all the 166 participants (56 %), a pancreatic
cystic lesion was detected during surveillance. Forty of
these 93 individuals (43 %) returned the questionnaire the
year prior to the detection of the cystic lesion (mean CWS-
score 13.3, standard deviation (SD) 3.6), as well as the
questionnaire in the year of the detection of the lesion
(mean CWS-score 12.5, SD 3.7). The difference in mean
CWS-score was not statistically significant (95 % CI for
the difference -0.3 to 1.9, P = 0.163). A total of 45
individuals (48 %) returned the questionnaire in the year of
detection (mean CWS-score 11.9, SD 3.5) as well as the
questionnaire 1 year after detection (mean CWS-score
11.9, SD 3.4). Again, the difference in mean CWS-score
between the 2 years was not statistically significant (95 %
CI for the difference -1.1 to 1.1, P = 0.97).
Impact of a recommended shortened surveillance
interval on cancer worries
For 25 out of 166 individuals (15 %), a shortened
surveillance interval was recommended; for 16 individuals
an interval of 3 months and for nine individuals an interval
of 6 months. Six of these 25 individuals (24 %) returned
the questionnaire in the year prior to the shortened
surveillance interval (mean CWS-score 14.3, SD 3.8), as
well as in the year of the shortened surveillance interval
(mean CWS-score 15.5, SD 4.7). The difference in mean
CWS-score of 1.2 points was not significant (95 % CI for
the difference -3.9 to 1.6, P = 0.33). Nine individuals
(36 %) returned the questionnaire in the year of the
shortened surveillance interval (mean CWS-score 14.4, SD
5.2), as well as in the year after (mean CWS-score 12.2, SD
4.5). This decrease in mean CWS-score by 2.2 points was
also not statistically significant (95 % CI for the difference
-1.0 to 5.4, P = 0.15).
Impact of pancreatic surgery on cancer worries
In 7 out of 166 individuals (4 %), pancreatic surgery was
performed. Two of these individuals returned both the
questionnaire from the year prior to surgery (mean CWS-
score 10.5 (SD 3.5), as well as the post-operative
Pancreatic surveillance
Psychological questionnaires
Intake by 
gastroenterologist
T0 
questionnaire
MRI & EUS
1st year
MRI & EUS
2nd year
Counseling by 
clinical geneticist
T1 
questionnaire
T3 
questionnaire
T2 
questionnaire
± 2-12 weeks ± 2-4 weeks 1 year
Fig. 1 Overview of both the clinical part of the pancreatic cancer surveillance study and the timing of the psychological questionnaires. MRI
magnetic resonance imaging, EUS endoscopic ultrasonography
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questionnaire in the year of surgery (mean CWS-score
11.0, SD 0.0). The difference in mean CWS-score was not
statistically significant (P = 0.87). Four cases returned
both the questionnaire in the year of surgery (mean CWS-
score 14.0, SD 3.5), as well as the questionnaire in the year
after surgery (mean CWS-score 11.8, SD 3.9). This
decrease in score by 2.2 points was not statistically sig-
nificant (95 % CI for the difference -7.9 to 12.4,
P = 0.53).
Discussion
In this prospective multicenter study, we assessed the
course of cancer worries over a 2-year period in high-risk
individuals participating in annual PDAC-surveillance,
assessed demographic baseline and psychosocial factors
that could be associated with these cancer worries, as well
as the impact of three clinical events on cancer worries.
Independently associated with cancer worries in the sec-
ond year of follow-up was having a family member that
was affected by PDAC below the age of 50.
Because PDAC-surveillance is being performed more
and more worldwide, it is key to take into account the
psychological aspects of repeated participation. Although
we previously reported a low general psychological burden
of annual participation in PDAC-surveillance [27], 33 %
of participants did have cancer-specific worries with a
CWS-score C14. While this is not a rigorously tested cut-
off point and there are no norm-data on cancer worries in
the general population, a score C14 is considered to be
indicative of moderate to high cancer worries [29]. It is
important to adequately and timely identify these indi-
viduals with cancer worries, because they would likely
benefit from psychosocial support to decrease or prevent
psychological distress. Psychosocial interventions, varying
from psycho-education and mindfulness-training to cog-
nitive behavioral therapy, have been proven to be effective
in reducing levels of distress to such levels that patients
can resume their daily activities.
Therefore, this study focused on cancer worries during
PDAC-surveillance, more specifically on the course of
cancer worries over time, on predictors of cancer worries,
and on cancer worries during certain events. To our current
knowledge, this is the first study with a prospective design
assessing these characteristics of cancer worries in indi-
viduals at inherited or familial high risk of developing
PDAC over time. Although much research was done into
generalized distress and levels of cancer worries, factors
influencing cancer worries were hardly studied in popu-
lations at inherited high risk of developing other types of
cancer [27, 30–34]. Sociodemographic and clinical vari-
ables found to be significantly associated with cancer-T
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specific distress for familial adenomatous polyposis (FAP)
were lower educational level, female gender, diagnosis of
FAP (as opposed to being at risk for FAP or being a non-
carrier), having a personal history of cancer, and having
had surgery more than 10 years ago [27]. In individuals
with Lynch syndrome, however, no difference for age,
gender, level of education, actual or perceived risk of
Lynch syndrome, or a personal history of cancer was found
[30]. In a Von Hippel–Lindau (VHL) population, factors
associated with VHL-related worries were diagnosis of, or
treatment for, VHL, a high level of social constraint, a high
perceived risk of developing tumors, and the loss of a close
relative due to VHL during adolescence [31].
As in our previous study [27], individual cancer worries
decreased over the 2-year period of surveillance in high-
risk individuals for PDAC. We identified a perceived ele-
vated risk of developing PDAC and having a family
member that was affected by PDAC under 50 years of age
as factors associated with cancer worries in the second year
of follow-up, the latter being independently associated.
Both factors resemble the findings by Lammens et al. [31],
who described a high perceived risk of developing tumors
and the loss of a close relative during adolescence as
related to cancer-specific worries.
Surprisingly, a factor not associated with high cancer
worries, was a personal history of cancer. This factor was
previously described as associated with high cancer worries
[27], and one might expect individuals who already had
cancer in the past to be more anxious of developing cancer
again, especially when being at high risk of this. Educa-
tional level was also not associated with high cancer
worries at the second year of follow-up, in contrast to a
previous study in FAP-individuals [27].
Table 4 Univariate and multivariate analysis for factors possibly associated with cancer worries in the second year of follow-up (T3)
Factors N (%)/mean (range, SD) Univariate
analyses
Multivariate
analysis
b P value b P value
Age at inclusion, mean (range, SD) 51 (19–73, 9.5) -0.142 0.126 0.010 0.924
Female gender 67 (57 %) 0.140 0.133 0.119 0.215
Carriership of a gene mutation 57 (49 %) 0.172 0.063 0.133 0.183
Number of PDAC cases in the family, mean (range, SD) 2 (0–7, 1.2) 0.058 0.538
Having a family member affected by PDAC\50 years of age 45 (39 %) 0.234 0.016 0.218 0.031
Having children 104 (89 %) 0.033 0.723
Being in a relationship 98 (84 %) -0.046 0.635
Education at college/university-level 85 (73 %) -0.001 0.995
Current or past smoker 50 (43 %) 0.140 0.143
Current or past alcohol consumer 81 (69 %) -0.031 0.744
Personal history of any type of cancer 35 (30 %) 0.048 0.610
Body Mass Index, mean (range, SD) 25.8 (10.0–43.8, 4.6) 0.085 0.233
Perception of moderately to strongly elevated risk of developing PDAC 69 (59 %) 0.228 0.013 0.163 0.109
Previous psychological support 17 (15 %) 0.181 0.053
Having someone available to confide in 111 (95 %) -0.077 0.407
SD standard deviation, PDAC pancreatic ductal adenocarcinoma
Bold P-values are considered statistically significant
T0 T1 T2 T3
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All individuals
Individuals with a family member affected by
PDAC <50 years of age
Individuals without a family member affected
by PDAC <50 years of age
Questionnaires
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Fig. 2 Mean CWS-scores at different moments in time, shown for all
individuals and for individuals with and without a family member that
was affected by pancreatic cancer under 50 years of age CWS cancer
worry scale, PDAC pancreatic ductal adenocarcinoma
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We also assessed three clinical events for association
with increased cancer worries: the detection of a cystic
lesion, a recommended shortened surveillance interval, and
undergoing pancreatic surgery. For all three events, we did
not find a significant change in CWS-score for the year
prior to the event and/or the year after the event in com-
parison to the year of the event. However, the CWS-score
in participants with a recommended shortened surveillance
interval did differ considerably between that year and the
year after the event, and so did the CWS-score in the
individuals who underwent surgery. This suggests that a
shortened surveillance interval and pancreatic surgery
cause a decrease in CWS-score the year after, possibly due
to relief at follow-up, however, our sample size for these
sub-analyses (n = 9 and n = 4) were likely too small to
find a statistically significant difference, which is also
demonstrated by the large 95 % confidence interval for the
differences in CWS-scores.
This study has several strengths. The prospective design in
a large group of individuals at high risk of developing pan-
creatic cancer is unique and of great scientific value.However,
this study also has some limitations, one ofwhichmight be the
power for our sub-analyses on clinical factors. Therefore, to
draw definite conclusions on these factors, a larger study
sample is needed. Also, because the questionnaire study was
added after the first inclusion period of the original clinical
study protocol, some participants had already had their first
investigations and therefore started their questionnaires at T2,
which resulted in a relatively low number of available T0
questionnaires in the analyzed cohort.
In conclusion, this prospective questionnaire study identi-
fied the factor ‘having a family member affected by PDAC
\50 years of age’ to be associated with cancer worries in the
second year of follow-up in individuals at inherited or familial
high risk of developing PDACwho are participating in annual
surveillance. Recognizing this factor can help clinicians to
timely identify individuals ‘at risk’ of a high level of cancer
worrieswhomwould likely benefit frompsychosocial support
to decrease or prevent psychological distress.
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